Patents Assigned to Sorrento Therapeutics, Inc.
-
Patent number: 11242391Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: January 14, 2020Date of Patent: February 8, 2022Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
-
Publication number: 20220025054Abstract: There is disclosed compositions and methods relating to anti-VEGFR2 antibodies. More specifically, there is disclosed fully human antibodies that bind VEGFR2, VEGFR2-binding fragments and derivatives of such antibodies, and VEGFR2-binding polypeptides comprising such fragments. Further still, there is disclosed antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having various cancers.Type: ApplicationFiled: July 29, 2021Publication date: January 27, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Randy Gastwirt, Heyue Zhou, John Dixon Gray, Guodi Lu
-
Patent number: 11219721Abstract: An attachment band for a fluid delivery apparatus includes an annular body having a wall defining a hollow inner space, an adjacent pair of attachment apertures extending through the wall, and an indicator aperture extending through the wall opposite the pair of attachment apertures. The indicator aperture includes an indicator portion that is configured to present an indication to a user of the fluid delivery apparatus of a tightness of the attachment band. A first strap extends radially outward from the annular body of the attachment band and is substantially aligned with the attachment apertures. A second strap extends radially outward from the annular body and is substantially aligned with the indicator aperture.Type: GrantFiled: December 5, 2017Date of Patent: January 11, 2022Assignee: Sorrento Therapeutics, Inc.Inventors: Russell F. Ross, Andrew T. Baker, Elizabeth D. Gadsby, Luke Hagan, Aaron Peck, Alyson Yamada, Pratap Ganapathy
-
Publication number: 20220002415Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: ApplicationFiled: September 22, 2021Publication date: January 6, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Publication number: 20220002422Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: September 22, 2021Publication date: January 6, 2022Applicant: Sorrento Therapeutics, Inc.Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
-
Patent number: 11213666Abstract: A method for administering a medicament to a patient includes placing a fluid delivery apparatus with the medicament in contact with a portion of the skin of said patient. A flow rate of the medicament from the fluid delivery apparatus is adjusted such that the medicament is delivered to the patient for a predetermined time period. The fluid delivery apparatus includes a controller assembly having a body component defining an axis and a plunger component slidably coupled to the body component. The plunger is positionable between a first position in which the plunger is nearest to the body component and a second position in which the plunger component is furthest from the body component. A bias assembly is positioned between the body component and the plunger component. The bias assembly is configured to apply a two stage force profile to the plunger component.Type: GrantFiled: December 5, 2017Date of Patent: January 4, 2022Assignee: Sorrento Therapeutics, Inc.Inventors: Russell F. Ross, Andrew T. Baker, Luke Hagan
-
Publication number: 20210395380Abstract: The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX4OL by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.Type: ApplicationFiled: August 23, 2021Publication date: December 23, 2021Applicant: Sorrento Therapeutics, Inc.Inventor: Min Soo Kim
-
Publication number: 20210393515Abstract: Disclosed herein are methods of administering resiniferatoxin (RTX) perineurally for treatment of maladaptive pain, and compositions for use in such methods.Type: ApplicationFiled: June 11, 2021Publication date: December 23, 2021Applicant: Sorrento Therapeutics, Inc.Inventor: Alexis Nahama
-
Publication number: 20210388097Abstract: The present disclosure provides BCMA binding proteins, particularly anti-BCMA antibodies, or antigen-binding portions thereof, that specifically bind BCMA and uses thereof. In one embodiment, the anti-BCMA antibody comprises an antigen binding portion that binds a human BCMA epitope and blocks binding (e.g, inhibits binding) of human APRIL and/or human BAFF to the human BCMA epitope. Various aspects of the anti-BCMA antibodies relate to antibody fragments, single-chain antibodies, pharmaceutical compositions, nucleic acids, recombinant expression vectors, host cells, and methods for preparing and using such anti-BCMA antibodies. Methods for using the anti-BCMA antibodies include in vitro and in vivo methods for binding BCMA, detecting BCMA and treating diseases associated with BCMA over-expression.Type: ApplicationFiled: August 25, 2021Publication date: December 16, 2021Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Xia Cao
-
Patent number: 11191845Abstract: There is disclosed an antibody drug conjugate (ADC) having an IgG antibody that binds to a CD38 target conjugated at a Cys site in the hinge region of an IgG antibody. There is further disclosed a method for treating multiple myeloma comprising providing an effective amount of a CD38 ADC.Type: GrantFiled: June 20, 2018Date of Patent: December 7, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: Tong Zhu, Alisher Khasanov, Gang Chen, Katherine Fells, Heyue Zhou, John Dixon Gray
-
Patent number: 11179555Abstract: A medical device for delivering a drug compound through a stratum corneum includes a support having an aperture, an array of microneedles extending outwardly from the support, a plurality of nanostructures associated with each microneedle, and a reservoir wherein the drug compound is retained. At least one microneedle contains a shaft extending from the support. The shaft includes a tip configured to penetrate the stratum corneum. The shaft defines a channel extending from the support to the tip. The channel is in at least partial alignment with the aperture. At least some of the microneedles of the array of microneedles each have a cross-sectional dimension of from about 1 micrometer to about 1 millimeter. At least some of the nanostructures have a cross-sectional dimension less than about 500 nanometers and greater than about 5 nanometers and an aspect ratio of from about 0.2 to about 5.Type: GrantFiled: March 22, 2019Date of Patent: November 23, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventor: Russell Frederick Ross
-
Patent number: 11180568Abstract: There is disclosed compositions and methods relating to or derived from anti-CD137 antibodies. More specifically, there is disclosed fully human antibodies that bind CD137, CD137-antibody binding fragments and derivatives of such antibodies, and CD137-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression. Diseases amenable to treatment is selected from the group consisting of cancers, autoimmune diseases and viral infections.Type: GrantFiled: February 8, 2019Date of Patent: November 23, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 11179554Abstract: A uniformity control membrane can be securely engaged against an upstream side of a microneedle array and configured so that resistance to flow through the uniformity control membrane is substantially greater than the resistance to flow through the microneedle array. These differences in flow resistance can facilitate uniform administration of a liquid formulation into the patient's skin across a broad area and at a relatively low pressure, such as by way of capillary action. The administration of the liquid formulation into the patient's skin across the broad area can result from the liquid formulation being administered by way of at least a majority of the microneedles of the microneedle array.Type: GrantFiled: April 17, 2017Date of Patent: November 23, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventors: Andrew T. Baker, Russell F. Ross, Elizabeth Deibler Gadsby, Luke Hagan
-
Publication number: 20210330787Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-L1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-L1, PD-L1-binding fragments and derivatives of such antibodies, and PD-L1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-L1 related disorders or conditions, including various inflammatory disorders and various cancers.Type: ApplicationFiled: May 3, 2021Publication date: October 28, 2021Applicant: Sorrento Therapeutics, Inc.Inventors: Heyue Zhou, Randy Gastwirt, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann
-
Patent number: 11155628Abstract: There is disclosed compositions and methods relating to or derived from anti-c-Met antibodies. More specifically, there is disclosed fully human antibodies that bind c-Met, c-Met-binding fragments and derivatives of such antibodies, and c-Met-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having c-Met related disorders or conditions, including various inflammatory disorders and various cancers.Type: GrantFiled: June 25, 2019Date of Patent: October 26, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: Barbara A. Swanson, Heyue Zhou, Yan-Liang Zhang, Randy Gastwirt, John Dixon Gray
-
Patent number: 11155623Abstract: There is disclosed compositions and methods relating to or derived from anti-CTLA4 antibodies. More specifically, there is disclosed fully human antibodies that bind CTLA4, CTLA4-antibody binding fragments and derivatives of such antibodies, and CTLA4-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating a disease requiring either stimulation of immune responses or suppression.Type: GrantFiled: January 8, 2019Date of Patent: October 26, 2021Assignee: Sorrento Therapeutics, Inc.Inventors: John Dixon Gray, Heyue Zhou
-
Patent number: 11142579Abstract: The present disclosure provides variant anti-OX40 antibodies that mimic the activity of OX40L by behaving as an agonist against receptor OX40 to enhance T cell clonal expansion and differentiation. The variant anti-OX40 antibodies exhibit improved binding affinity for OX40 and improved agnostic activity, compared to a wild type anti-OX40 antibody (wild type 2B4 clone) from which the variant clones are derived. The variant anti-OX40 antibodies specifically bind OX40 receptors on activated T lymphocytes, stimulate proliferation of effector T cells, stimulate proliferation of effector T cells in the presence of regulatory T cells, and stimulate production of at least one cytokine from effector T cells.Type: GrantFiled: December 6, 2018Date of Patent: October 12, 2021Assignee: Sorrento Therapeutics, Inc.Inventor: Min Soo Kim
-
Patent number: 11135414Abstract: Disclosed are medical devices that incorporate siRNA. In addition to one or more siRNA constructs, devices include nanostructures fabricated on a surface to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes. Microneedles may be incorporated on devices. The pattern including nanostructures may be formed on the surface of the microneedles.Type: GrantFiled: July 20, 2018Date of Patent: October 5, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventor: Russell Frederick Ross
-
Publication number: 20210299090Abstract: There is disclosed a method for treating Parkinson's Disease (PD) comprising administering an effective amount of Resiniferatoxin (RTX) by an intrathecal or intracisternal administration. In some embodiments, the dose of RTX for an adult human is from about 0.1 ?g to about 100 ?g.Type: ApplicationFiled: June 11, 2021Publication date: September 30, 2021Applicant: Sorrento Therapeutics, Inc.Inventors: Alexis Nahama, Henry Hongjun Ji
-
Patent number: 11129975Abstract: A device and method for delivering a high viscosity composition is described. The composition includes a bioactive agent for delivery to a subject in need thereof. The method delivers the bioactive agent at a high bioavailability and with little loss of agent to the natural defense mechanisms of the body. The device includes one or more microneedles with structures fabricated on a surface of the microneedles to form a nanotopography. A random or non-random pattern of structures may be fabricated such as a complex pattern including structures of differing sizes and/or shapes.Type: GrantFiled: January 10, 2019Date of Patent: September 28, 2021Assignee: SORRENTO THERAPEUTICS, INC.Inventor: Russell F. Ross